CVL-562 is under clinical development by Cerevel Therapeutics and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs for Schizophrenia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CVL-562’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CVL-562 overview
CVL-562 (PF-06412562) is under development for the treatment of Schizophrenia. The drug candidate is a new molecular entity (NME). The drug candidate is administered through oral route as a tablet. It acts by targeting dopamine receptor 1. It was also under development for cognitive disorders and Parkinson's disease.
Cerevel Therapeutics overview
Cerevel Therapeutics is a biopharmaceutical company which develops and commercializes medicines for the treatment of central nervous system disorders. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CVL-562’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
